BACKGROUND: Patients with various structural brain lesions often suffer from seizures. Refractory epilepsy is the most common in brain tumors, vascular malformations, and sequel of cerebral infections, infarcts or trauma.
OBJECTIVE: To evaluate the efficacy and safety of new AEDs in patients with medically refractory seizures associated with structural brain lesions.
MATERIAL AND METHODS: Twenty-six (26) patients (8 M; 18 F), aged 48.4± 7.6 years, with simple (65%) or complex partial (35%) seizures associated with cerebral tumors (12 p) and non-neoplastic brain lesions (14 p) were included in the study. Diagnosis was based on the criteria of ILAE. Patients were treated with OXC (10 cases), LTG (9 cases), and LEV (7 cases) for at least six months. Efficacy and tolerability were assessed on the basis of changes in seizure frequency and reporting the drugs side effects. Structural neuroimaging, EEG, and clinical follow-up were performed before and after AEDs addition.
RESULTS: Eighteen (18) patients (72%) were seizure-free after six to twenty-four months treatment period and 8 (28%) experienced some rare partial seizures but no more generalized attacks. Side effect of mild somnolence was observed in 4 patients treated with LTG during the first 3 weeks of the treatment, of transient dizziness in 3 patients under OXC, and transient fatigue in 2 patients treated with LEV.
CONCLUSION: In accordance with our own findings and literature review, we suggest that new AEDs due to their efficacy and good safety profile might be useful for the epilepsy control in patients with medically refractory seizures associated with structural brain lesions.
Berg A, Berkovic S, Brodie M et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51 (4): 676 - 685.
Drugs for epilepsy. Treatment guidelines from the medical letter, 2005, 3(39): 75-82.
Freidel M., Krause E., Kuhn K, Peper R., Vogel H. Oxcarbazepine in the treatment of epilepsy: An open-labelled, prospective, post-marketing surveillance study with oxcarbazepine in the treatment of 1385 patients with epilepsy. Fortschr Neurol Psychiatr, 2007, 75(2): 100-106.
Hildebrand J. The use of anti-epileptic drugs in neuro-oncology. Educational book, Fifth Congress of EANO, 2004, 179-183.
Hitiris N., Brodie M. Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol, 2006, 2(19): 175-180.
Hovinga C. Levetiracetam: A novel antiepileptic drug. Medscape Neurology and Neurosurgery, Jan 2001.
Mangano F., McBride A., Schneider S. Brain tumors and epilepsy. In: Managing epilepsy and co-existing disorders. eds. Ettinger A., Devinsky O., Boston, Butterworth-Heinemann, 2002, 175-194.
Maschio M., Dinapoli L et al. Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol, 2008, 1(86): 61-70.
Maschio M., Dinapoli L et al. The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Experim Clin Can Res, 2009, 28:60.
Mendiratta A., Hircsh L. Management of epilepsy in elderly. In: The Treatment of Epilepsy, Shorvorn S., Perucca E, Engel J (eds). Wiley-Blackwell, 2009, p.203-218.
Pellock, J. Overview of Lamotrigine and new antiepileptic drugs in the challenge. J. Child Neurol., 1997, 12, Suppl. I, S48-S52.
Pellock. J. Treatment of epilepsy in the new millennium. Pharmacother, 2000, 20, 129-138S.
Van Breemen M., Vecht Ch. Optimal seizure management in brain tumor patients. J Curr Neurol Neurosci Rep, 2005, 3(5): 207-213.
Email this article (Login required) 
